Tafamidis is a drug that may reduce deaths and hospitalizations in patients with transthyretin amyloid cardiomyopathy (ATTR-CM). If tafamidis receives FDA approval for transthyretin amyloid cardiomyopathy, it may offer the first medical treatment for this life-threatening disease.
from Medindia Health News https://ift.tt/2Lyae6q
No comments:
Post a Comment